TWA
CRVS icon

TCI Wealth Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

TCI Wealth Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-500
Closed -$455 – 666
2023
Q1 		$455 Hold
500
– – ﹤0.01% 2229
2022
Q4 		$425 Sell
500
-300
-38% -$265 ﹤0.01% 2243
2022
Q3 		$1K Hold
800
– – ﹤0.01% 2062
2022
Q2 		$1K Buy
800
+400
+100% +$491 ﹤0.01% 2110
2022
Q1 		$1K Hold
400
– – ﹤0.01% 2083
2021
Q4 		$1K Buy
400
+100
+33% +$388 ﹤0.01% 2175
2021
Q3 		$1K Buy
+300
New +$888 ﹤0.01% 2245

Other funds holding CRVS

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
SC
Samlyn Capital New York $5.82B AUM 36.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $93.4B AUM 35.1% 1-Year Est. Return